FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

FDA Approves J&J’s Self-Injection Psoriasis Pen

Feb. 4, 2019

The FDA has approved Johnson & Johnson’s self-injected pen for Tremfya, a psoriasis treatment for adults with moderate to severe forms of the skin condition.

The biologic selectively blocks interleukin-23, a main cytokine in inflammatory diseases. The 100 mg dose is injected under the skin at weeks zero and four, and every eight weeks after.

After being shown how to inject the treatment by a dermatologist, psoriasis patients can self-inject at home.

View today's stories